Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial

Addiction

Volumn 112, Issue 1, 2017, Pages 156-167

  Hatsukami, Dorothy K ^a,b   Luo, Xianghua ^a,c   Dick, Laura ^a   Kangkum, Margarita ^a   Allen, Sharon S ^b   Murphy, Sharon E ^a   Hecht, Stephen S ^a   Shields, Peter G ^d   al'Absi, Mustafa ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Alternative nicotine delivery systems; electronic cigarettes; exposure biomarkers; medicinal nicotine; nicotine regulation; product standards; reduced nicotine content cigarettes; smokeless tobacco

Indexed keywords

BIOLOGICAL MARKER; NICOTINE; NICOTINE GUM;

ADULT; ANALYSIS; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TOBACCO; URINE;

ADULT; BIOMARKERS; CIGARETTE SMOKING; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; TOBACCO PRODUCTS; TOBACCO USE CESSATION PRODUCTS;

EID: 84995922918     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13603     Document Type: Article

References (41)

1. Jamal A., Homa D. M., O'connor E., Babb S. D., Caraballo R. S., Singh T. et al. Current cigarette smoking among adults—United States, 2005–2014. Morb Mortal Wkly Rep 2015; 64: 1233–1240.
2. Eriksen M. P., Mackay J., Schluger N., Islami F., Drope J. The Tobacco Atlas. Atlanta. GA: American Cancer Society; 2015.
3. Warner K. E. An endgame for tobacco? Tob Control 2013; 22: i3–5.
4. World Health Organization (WHO). In: WHO Study Group on Tobacco Product Regulation (TobReg), editor. Advisory Note: Global Nicotine Reduction Strategy. Geneva, Switzerland: World Health Organization; 2015.
5. Royal College of Physicians (RCP). Nicotine Without Smoke: Tobacco Harm Reduction. London: RCP; 2016.
6. Donny E. C., Denlinger R. L., Tidey J. W., Koopmeiners J. S., Benowitz N. L., Vandrey R. G. et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med 2015; 373: 1340–1349.
7. Hatsukami D. K., Kotlyar M., Hertsgaard L. A., Zhang Y., Carmella S. G., Jensen J. A. et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010; 105: 343.
8. Hatsukami D. K., Hertsgaard L. A., Vogel R. I., Jensen J. A., Murphy S. E., Hecht S. S. et al. Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev 2013; 22: 1015–1024.
9. Benowitz N. L., Hall S. M., Stewart S., Wilson M., Dempsey D., Jacob P. III. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev 2007; 16: 2479–2485.
10. Benowitz N. L., Dains K. M., Hall S. M., Stewart S., Wilson M., Dempsey D. et al. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev 2012; 21: 761–769.
11. Nardone N., Donny E. C., Hatsukami D. K., Koopmeiners J. S., Murphy S. E., Strasser A. A. et al. Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. Addiction 2016; DOI: 10.1111/add.13519.
12. Hatsukami D. K., Heishman S. J., Vogel R. I., Denlinger R. L., Roper-Batker A. N., Mackowick K. M. et al. Dose–response effects of spectrum research cigarettes. Nicotine Tob Res 2013; 15: 1113–1121.
13. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127.
14. Robinson S. M., Sobell L. C., Sobell M. B., Leo G. I. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav 2014; 28: 154–162.
15. Sobell L. C., Sobell M. B. Timeline follow-back. A technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J. P., editors. Measuring Alcohol Consumption Psychosocial and Biochemical Methods. New York, NY: Springer-Verlag; 1992, pp. 41–72.
16. Murphy S. E., Park S. S., Thompson E. F., Wilkens L. R., Patel Y., Stram D. O. et al. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. Carcinogenesis 2014; 35: 2526–2533.
17. Scherer G., Engl J., Urban M., Gilch G., Janket D., Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007; 47: 171–183.
18. Carmella S. G., Ming X., Olvera N., Brookmeyer C., Yoder A., Hecht S. S. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem Res Toxicol 2013; 26: 1209–1217.
19. Yuan J. M., Knezevich A. D., Wang R., Gao Y. T., Hecht S. S., Stepanov I. Urinary levels of the tobacco-specific carcinogen N′-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011; 32: 1366–1371.
20. Stepanov I., Hecht S. S. Detection and quantitation of N′-nitrosonornicotine in human toenails by liquid chromatography-electrospray ionization-tandem mass spectrometry. Cancer Epidemiol Biomarkers Prev 2008; 17: 945–948.
21. Diggle P. J., Heagerty P. J., Liang K.-Y., Zeger S. L. Analysis of Longitudinal Data, 2nd edn. Oxford: Oxford University Press; 2002.
22. Hatsukami D. K., Perkins K. A., Lesage M. G., Ashley D. L., Henningfield J. E., Benowitz N. L. et al. Nicotine reduction revisited: science and future directions. Tob Control 2010; 19: e1–10.
23. Kozlowski L. T. Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy. Tob Control 2016; DOI: 10.1136/tobaccocontrol-2016-052995.
24. Borland R. Paying more attention to the ‘elephant in the room’. Tob Control 2016; DOI: 10.1136/tobaccocontrol-2016-053150.
25. Rupprecht L. E., Smith T. T., Schassburger R. L., Buffalari D. M., Sved A. F., Donny E. C. Behavioral mechanisms underlying nicotine reinforcement. Curr Top Behav Neurosci 2015; 24: 19–53.
26. Zeller M., Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 2009; 18: 324–332.
27. Hatsukami D. K., Joseph A. M., Lesage M., Jensen J., Murphy S. E., Pentel P. R., et al. Developing the science base for reducing tobacco harm. Nicotine Tob Res 2007; 9: S537–53.
28. Etter J. F. Electronic cigarettes: a survey of users. BMC Public Health 2010; 10: 231.
29. Mcrobbie H., Bullen C., Hartmann-Boyce J., Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014; 12: CD010216.
30. Vansickel A. R., Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 2013; 15: 267–270.
31. Lopez A. A., Hiler M. M., Soule E. K., Ramoa C. P., Karaoghlanian N. V., Lipato T. et al. Effects of electronic cigarette liquid nicotine concentration on plasma nicotine and puff topography in tobacco cigarette smokers: a preliminary Report. Nicotine Tob Res 2016; 18: 720–723.
32. Ramoa C. P., Hiler M. M., Spindle T. R., Lopez A. A., Karaoghlanian N., Lipato T. et al. Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. Tob Control 2016; 25: e6–9.
33. Shihadeh A., Eissenberg T. Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux. Nicotine Tob Res 2015; 17: 158–162.
34. Biener L., Roman A. M., Mc Inerney S. A., Bolcic-Jankovic D., Hatsukami D. K., Loukas A. et al. Snus use and rejection in the USA. Tob Control 2016; 25: 386–392.
35. Mcmillen R., Maduka J., Winickoff J. Use of emerging tobacco products in the United States. J Environ Public Health 2012; 2012: 989474.
36. King B. A., Dube S. R., Tynan M. A. Current tobacco use among adults in the United States: findings from the National Adult Tobacco Survey. Am J Public Health 2012; 102: e93–100.
37. Berg C. J., Haardoerfer R., Escoffery C., Zheng P., Kegler M. Cigarette users’ interest in using or switching to electronic nicotine delivery systems for smokeless tobacco for harm reduction, cessation, or novelty: a cross-sectional survey of US adults. Nicotine Tob Res 2015; 17: 245–255.
38. Brandon T. H., Goniewicz M. L., Hanna N. H., Hatsukami D. K., Herbst R. S., Hobin J. A. et al. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res 2015; 21: 514–525.
39. World Health Organization (WHO). WHO report on the global tobacco epidemic Raising Taxes on Tobacco. Geneva, Switzerland: World Health Organization; 2015.
40. Cobb N. K., Abrams D. B. The FDA, e-cigarettes, and the demise of combusted tobacco. N Engl J Med 2014; 371: 1469–1471.
41. Mcneill A., Brose L. S., Calder R., Hitchman S. C., Hajek P., Mcrobbie H. E-cigarettes: an evidence update. A report commissioned by Public Health England. London, UK: Public Health England; 2015.